JP2017506659A5 - - Google Patents

Download PDF

Info

Publication number: JP2017506659A5
Authority: JP; Japan
Prior art keywords: pyrrolo; pyrimidin; pyrazol; trifluoromethyl; acetonitrile
Prior art date: 2015-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016554471A

Other languages

English (en)

Japanese (ja)

Other versions

JP6576941B2 (ja

JP2017506659A (ja

Filing date

2015-02-27

Publication date

2018-04-12

2015-02-27 Application filed filed Critical

2015-02-27 Priority claimed from PCT/US2015/017963 external-priority patent/WO2015131031A1/en

2017-03-09 Publication of JP2017506659A publication Critical patent/JP2017506659A/ja

2018-04-12 Publication of JP2017506659A5 publication Critical patent/JP2017506659A5/ja

2019-09-18 Application granted granted Critical

2019-09-18 Publication of JP6576941B2 publication Critical patent/JP6576941B2/ja

Status Active legal-status Critical Current

2035-02-27 Anticipated expiration legal-status Critical

Links

239000003814 drug Substances 0.000 claims 20
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 13
-1 7H-pyrrolo [2,3-d] pyrimidin-4-yl Chemical group 0.000 claims 12
201000003793 Myelodysplastic syndrome Diseases 0.000 claims 12
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 6
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 3
208000009527 Refractory anemia Diseases 0.000 claims 3
206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 3
229940124639 Selective inhibitor Drugs 0.000 claims 3
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 3
229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 2
206010058314 Dysplasia Diseases 0.000 claims 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
206010033661 Pancytopenia Diseases 0.000 claims 2
208000024389 cytopenia Diseases 0.000 claims 2
239000003968 dna methyltransferase inhibitor Substances 0.000 claims 2
230000010437 erythropoiesis Effects 0.000 claims 2
239000003112 inhibitor Substances 0.000 claims 2
230000011987 methylation Effects 0.000 claims 2
238000007069 methylation reaction Methods 0.000 claims 2
150000003839 salts Chemical class 0.000 claims 2
230000004936 stimulating effect Effects 0.000 claims 2
229940124597 therapeutic agent Drugs 0.000 claims 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 claims 1
GDLFDECNYGKCOB-UHFFFAOYSA-N 2-[1-[4-[4-(ethylaminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxycyclohexyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=CC(CNCC)=CC(OC2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 GDLFDECNYGKCOB-UHFFFAOYSA-N 0.000 claims 1
UMIFYBHMXIAHSA-NSQNTRMNSA-N 2-[1-[4-[4-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-6-(trifluoromethyl)pyridin-2-yl]oxycyclohexyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1[C@H](O)CCN1CC1=CC(OC2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=NC(C(F)(F)F)=C1 UMIFYBHMXIAHSA-NSQNTRMNSA-N 0.000 claims 1
RXXCVKTUMMDIRR-UHFFFAOYSA-N 2-[1-[4-[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxycyclohexyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=NC(CCO)=CC(OC2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 RXXCVKTUMMDIRR-UHFFFAOYSA-N 0.000 claims 1
QFPGZAJRDFHPCE-UHFFFAOYSA-N 2-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-1-[1-[2-(trifluoromethyl)pyrimidine-4-carbonyl]piperidin-4-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)C1=NC=CC(C(=O)N2CCC(CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 QFPGZAJRDFHPCE-UHFFFAOYSA-N 0.000 claims 1
UHPOZFYNJIMRCT-UHFFFAOYSA-N 3-[1-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical group ClC1=CC=CC(N2CC(CC2)C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 UHPOZFYNJIMRCT-UHFFFAOYSA-N 0.000 claims 1
HTGGWBJDPLPEPS-UHFFFAOYSA-N 3-[1-([1,3]oxazolo[5,4-b]pyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1CN(C=2OC3=NC=CC=C3N=2)CC1C(CC#N)N(N=C1)C=C1C1=NC=NC2=C1C=CN2 HTGGWBJDPLPEPS-UHFFFAOYSA-N 0.000 claims 1
UHEIPWYAZVECGS-ZDUSSCGKSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-n-[(2s)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)N[C@@H](C)C(F)(F)F)=CC(F)=C1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C1 UHEIPWYAZVECGS-ZDUSSCGKSA-N 0.000 claims 1
RZUCZMLSGAQMJN-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 RZUCZMLSGAQMJN-UHFFFAOYSA-N 0.000 claims 1
VCJFOLMEZCAWFO-UHFFFAOYSA-N 4-[4-(2-fluoro-4-isocyanobenzoyl)piperazin-1-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound FC1=CC([N+]#[C-])=CC=C1C(=O)N1CCN(CC(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 VCJFOLMEZCAWFO-UHFFFAOYSA-N 0.000 claims 1
CEIFLXZQZIUBTK-UHFFFAOYSA-N 4-[4-[3-[(dimethylamino)methyl]-5-fluorophenoxy]piperidin-1-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound CN(C)CC1=CC(F)=CC(OC2CCN(CC(CC#N)N3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)CC2)=C1 CEIFLXZQZIUBTK-UHFFFAOYSA-N 0.000 claims 1
VQDFOOLMNPPTBD-UHFFFAOYSA-N 4-[4-[3-cyano-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propyl]piperazine-1-carbonyl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1C(=O)N1CCN(CC(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 VQDFOOLMNPPTBD-UHFFFAOYSA-N 0.000 claims 1
MDDZCYJCJQHUCB-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-propan-2-ylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CN=C1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)C1 MDDZCYJCJQHUCB-UHFFFAOYSA-N 0.000 claims 1
NQSJETFQTIKWPX-UHFFFAOYSA-N 5-[3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-n-propan-2-ylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC(C)C)=CN=C1N1CC(CC#N)(N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)C1 NQSJETFQTIKWPX-UHFFFAOYSA-N 0.000 claims 1
XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
UMIFYBHMXIAHSA-KMDXXIMOSA-N C1[C@@H](O)CCN1CC1=CC(O[C@@H]2CC[C@@H](CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=NC(C(F)(F)F)=C1 Chemical compound C1[C@@H](O)CCN1CC1=CC(O[C@@H]2CC[C@@H](CC2)N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=NC(C(F)(F)F)=C1 UMIFYBHMXIAHSA-KMDXXIMOSA-N 0.000 claims 1
RUJXSBAUCVPXQZ-UHFFFAOYSA-N CC(C)(O)c1cc(OC2CCC(CC2)N2C[N+](CC#N)(C2)n2cc(cn2)-c2ncnc3[nH]ccc23)nc(c1)C(F)(F)F Chemical compound CC(C)(O)c1cc(OC2CCC(CC2)N2C[N+](CC#N)(C2)n2cc(cn2)-c2ncnc3[nH]ccc23)nc(c1)C(F)(F)F RUJXSBAUCVPXQZ-UHFFFAOYSA-N 0.000 claims 1
208000031404 Chromosome Aberrations Diseases 0.000 claims 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
108010036949 Cyclosporine Proteins 0.000 claims 1
108010008165 Etanercept Proteins 0.000 claims 1
CMKBSHGTPCCVOM-UHFFFAOYSA-N FC(F)(F)C1=CC(CCO)=CC(OC2CCN(CC2)C2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 Chemical compound FC(F)(F)C1=CC(CCO)=CC(OC2CCN(CC2)C2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 CMKBSHGTPCCVOM-UHFFFAOYSA-N 0.000 claims 1
FHTRVONXSDSHCU-SPCUYXFBSA-N FC(F)(F)C1=CC(CNC[C@H](O)C)=CC(OC2CCN(CC2)C2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 Chemical compound FC(F)(F)C1=CC(CNC[C@H](O)C)=CC(OC2CCN(CC2)C2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 FHTRVONXSDSHCU-SPCUYXFBSA-N 0.000 claims 1
108010044091 Globulins Proteins 0.000 claims 1
102000006395 Globulins Human genes 0.000 claims 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 1
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 1
208000034442 Refractory anemia with excess blasts type 1 Diseases 0.000 claims 1
208000034432 Refractory anemia with excess blasts type 2 Diseases 0.000 claims 1
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
230000001494 anti-thymocyte effect Effects 0.000 claims 1
210000000601 blood cell Anatomy 0.000 claims 1
210000004027 cell Anatomy 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229960001265 ciclosporin Drugs 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
229930182912 cyclosporin Natural products 0.000 claims 1
229960003603 decitabine Drugs 0.000 claims 1
230000001419 dependent effect Effects 0.000 claims 1
210000003743 erythrocyte Anatomy 0.000 claims 1
229960000403 etanercept Drugs 0.000 claims 1
210000003714 granulocyte Anatomy 0.000 claims 1
229960000598 infliximab Drugs 0.000 claims 1
229910052742 iron Inorganic materials 0.000 claims 1
229960004942 lenalidomide Drugs 0.000 claims 1
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
239000003607 modifier Substances 0.000 claims 1
210000001616 monocyte Anatomy 0.000 claims 1
208000012846 myelodysplastic syndrome with excess blasts-1 Diseases 0.000 claims 1
208000012847 myelodysplastic syndrome with excess blasts-2 Diseases 0.000 claims 1
ZBXHNCURDISBRO-UHFFFAOYSA-N n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O ZBXHNCURDISBRO-UHFFFAOYSA-N 0.000 claims 1
229960000688 pomalidomide Drugs 0.000 claims 1
UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
229960003433 thalidomide Drugs 0.000 claims 1

JP2016554471A 2014-02-28 2015-02-27 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 Active JP6576941B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461946124P	2014-02-28	2014-02-28
US61/946,124		2014-02-28
PCT/US2015/017963 WO2015131031A1 (en)	2014-02-28	2015-02-27	Jak1 inhibitors for the treatment of myelodysplastic syndromes

Publications (3)

Publication Number	Publication Date
JP2017506659A JP2017506659A (ja)	2017-03-09
JP2017506659A5 true JP2017506659A5 (2)	2018-04-12
JP6576941B2 JP6576941B2 (ja)	2019-09-18

Family

ID=52693052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016554471A Active JP6576941B2 (ja)	2014-02-28	2015-02-27	骨髄異形成症候群の治療のためのｊａｋ１阻害剤

Country Status (29)

Country	Link
US (4)	US20150246046A1 (2)
EP (1)	EP3110409B1 (2)
JP (1)	JP6576941B2 (2)
KR (1)	KR20160136323A (2)
CN (2)	CN112494652A (2)
AU (1)	AU2015222913B2 (2)
CA (1)	CA2940659C (2)
CL (1)	CL2016002144A1 (2)
CR (1)	CR20160449A (2)
CY (1)	CY1120857T1 (2)
DK (1)	DK3110409T3 (2)
EA (1)	EA201691745A1 (2)
ES (1)	ES2688553T3 (2)
HR (1)	HRP20181661T1 (2)
HU (1)	HUE041456T2 (2)
IL (1)	IL247475B (2)
LT (1)	LT3110409T (2)
MX (1)	MX372939B (2)
MY (1)	MY185392A (2)
PE (1)	PE20161388A1 (2)
PL (1)	PL3110409T3 (2)
PT (1)	PT3110409T (2)
RS (1)	RS57723B1 (2)
SG (2)	SG11201607083VA (2)
SI (1)	SI3110409T1 (2)
SM (1)	SMT201800551T1 (2)
UA (1)	UA121857C2 (2)
WO (1)	WO2015131031A1 (2)
ZA (1)	ZA201606610B (2)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10202003901UA (en)	2005-12-13	2020-05-28	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko)	2007-06-13	2015-04-07	인사이트 코포레이션	야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
SI2432472T1 (sl)	2009-05-22	2019-11-29	Incyte Holdings Corp	3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es)	2010-05-21	2013-02-27	Incyte Corp	Formulacion topica para un inhibidor de jak
PE20140146A1 (es)	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh)	2011-06-20	2016-02-24	因塞特控股公司	作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
TWI646099B (zh)	2012-11-01	2019-01-01	英塞特控股公司	作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
PH12020551186B1 (en)	2012-11-15	2024-03-20	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
ES2649156T3 (es)	2013-01-14	2018-01-10	Incyte Holdings Corporation	Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es)	2013-01-15	2019-09-18	Incyte Holdings Corp	Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
RS62867B1 (sr)	2013-03-06	2022-02-28	Incyte Holdings Corp	Postupci i intermedijeri za dobijanje inhibitora jak
HUE033587T2 (hu)	2013-05-17	2017-12-28	Incyte Corp	Bipirazol-származékok mint JAK inhibitorok
SMT202000315T1 (it)	2013-08-07	2020-07-08	Incyte Corp	Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA201690458A1 (ru)	2013-08-23	2016-07-29	Инсайт Корпорейшн	Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
SI3129021T1 (sl)	2014-04-08	2021-07-30	Incyte Corporation	Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K
MA39987A (fr)	2014-04-30	2017-03-08	Incyte Corp	Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en)	2015-05-29	2016-12-08	Incyte Corporation	Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
CN109072190A (zh) *	2016-03-09	2018-12-21	蔚山大学校产学协力团	将jak1抑制剂作为有效成分包含的用于干细胞的增殖、分化促进或老化抑制的组成物
KR101934107B1 (ko) *	2016-12-15	2018-12-31	가톨릭대학교산학협력단	골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물
CA3055233C (en)	2017-01-23	2022-08-09	Shanghai Longwood Biopharmaceuticals Co., Ltd.	Jak kinase inhibitor and preparation method and use thereof
CN109867676B (zh) *	2017-12-01	2020-10-30	北京普祺医药科技有限公司	一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en)	2018-01-30	2020-08-28	Incyte Corp	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
JP7410034B2 (ja)	2018-02-01	2024-01-09	シファメド・ホールディングス・エルエルシー	血管内血液ポンプならびに使用および製造の方法
KR102925957B1 (ko)	2018-02-16	2026-02-11	인사이트 코포레이션	사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
SMT202400306T1 (it)	2018-03-30	2024-09-16	Incyte Corp	Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
MA52655A (fr)	2018-03-30	2021-02-17	Incyte Corp	Biomarqueurs pour maladie cutanée inflammatoire
CA3097025A1 (en)	2018-04-13	2019-10-17	Incyte Corporation	Biomarkers for graft-versus-host disease
SG11202011680YA (en)	2018-06-01	2020-12-30	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
EP3873476A1 (en) *	2018-10-31	2021-09-08	Stemline Therapeutics, Inc.	Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
CA3117969A1 (en)	2018-10-31	2020-05-07	Incyte Corporation	Combination therapy for treatment of hematological diseases
CN111320633B (zh) *	2018-12-14	2022-09-27	中国医药研究开发中心有限公司	吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
WO2020181034A1 (en) *	2019-03-05	2020-09-10	Incyte Corporation	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US20220372135A1 (en)	2019-09-27	2022-11-24	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
EP4041204A1 (en)	2019-10-10	2022-08-17	Incyte Corporation	Biomarkers for graft-versus-host disease
WO2021072098A1 (en)	2019-10-10	2021-04-15	Incyte Corporation	Biomarkers for graft-versus-host disease
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN111358791A (zh) *	2020-03-13	2020-07-03	深圳百奥捷生物科技有限公司	Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用
MX2022015221A (es)	2020-06-02	2023-03-08	Incyte Corp	Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CA3204374A1 (en)	2020-12-08	2022-06-16	Incyte Corporation	Jak1 pathway inhibitors for the treatment of vitiligo
ES3057099T3 (en) *	2021-01-18	2026-02-26	Active Biotech Ab	Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
UA129643C2 (uk)	2021-05-03	2025-06-18	Інсайт Корпорейшн	Інгібітори шляху jak1 для лікування вузлуватого свербця
TW202509019A (zh) *	2023-04-27	2025-03-01	香港商維泰瑞隆（香港）生物科技有限公司	Sarm1調節子、其製劑及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt)	1998-08-11	2010-06-11	Novartis Ag	Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
KR100786927B1 (ko)	2000-06-28	2007-12-17	스미스클라인비이참피이엘시이	습식 분쇄방법
BR0212760A (pt)	2001-09-19	2004-12-07	Aventis Pharma Sa	Compostos quìmicos
DE60213842T2 (de)	2001-10-30	2007-09-06	Novartis Ag	Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es)	2002-05-29	2004-09-28	Novartis Ag	Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
TWI335913B (en)	2002-11-15	2011-01-11	Vertex Pharma	Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en)	2004-11-24	2006-06-01	Novartis Ag	Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
WO2006067445A2 (en)	2004-12-22	2006-06-29	Astrazeneca Ab	Csf-1r kinase inhibitors
SG10202003901UA (en)	2005-12-13	2020-05-28	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
HUE029767T2 (en)	2008-03-11	2017-04-28	Incyte Holdings Corp	JAK inhibitor azetidine and cyclobutane derivatives
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20140146A1 (es) *	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
AU2011335882B2 (en) *	2010-12-03	2016-03-10	Ym Biosciences Australia Pty Ltd	Treatment of JAK2-mediated conditions
CN103797010B (zh) *	2011-06-20	2016-02-24	因塞特控股公司	作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) *	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US10155987B2 (en) *	2012-06-12	2018-12-18	Dana-Farber Cancer Institute, Inc.	Methods of predicting resistance to JAK inhibitor therapy
TWI646099B (zh) *	2012-11-01	2019-01-01	英塞特控股公司	作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
HUE033587T2 (hu) *	2013-05-17	2017-12-28	Incyte Corp	Bipirazol-származékok mint JAK inhibitorok

2015
- 2015-02-27 KR KR1020167026668A patent/KR20160136323A/ko not_active Ceased
- 2015-02-27 SM SM20180551T patent/SMT201800551T1/it unknown
- 2015-02-27 PE PE2016001538A patent/PE20161388A1/es unknown
- 2015-02-27 LT LTEP15710994.3T patent/LT3110409T/lt unknown
- 2015-02-27 DK DK15710994.3T patent/DK3110409T3/en active
- 2015-02-27 ES ES15710994.3T patent/ES2688553T3/es active Active
- 2015-02-27 EA EA201691745A patent/EA201691745A1/ru unknown
- 2015-02-27 MX MX2016011103A patent/MX372939B/es active IP Right Grant
- 2015-02-27 CA CA2940659A patent/CA2940659C/en active Active
- 2015-02-27 UA UAA201609815A patent/UA121857C2/uk unknown
- 2015-02-27 HR HRP20181661TT patent/HRP20181661T1/hr unknown
- 2015-02-27 MY MYPI2016001574A patent/MY185392A/en unknown
- 2015-02-27 SG SG11201607083VA patent/SG11201607083VA/en unknown
- 2015-02-27 EP EP15710994.3A patent/EP3110409B1/en active Active
- 2015-02-27 SI SI201530368T patent/SI3110409T1/sl unknown
- 2015-02-27 JP JP2016554471A patent/JP6576941B2/ja active Active
- 2015-02-27 CN CN202010986614.7A patent/CN112494652A/zh active Pending
- 2015-02-27 WO PCT/US2015/017963 patent/WO2015131031A1/en not_active Ceased
- 2015-02-27 SG SG10201807952PA patent/SG10201807952PA/en unknown
- 2015-02-27 RS RS20181194A patent/RS57723B1/sr unknown
- 2015-02-27 CR CR20160449A patent/CR20160449A/es unknown
- 2015-02-27 CN CN201580017178.XA patent/CN106456773A/zh active Pending
- 2015-02-27 AU AU2015222913A patent/AU2015222913B2/en active Active
- 2015-02-27 PT PT15710994T patent/PT3110409T/pt unknown
- 2015-02-27 HU HUE15710994A patent/HUE041456T2/hu unknown
- 2015-02-27 PL PL15710994T patent/PL3110409T3/pl unknown
- 2015-02-27 US US14/633,605 patent/US20150246046A1/en not_active Abandoned
2016
- 2016-08-24 CL CL2016002144A patent/CL2016002144A1/es unknown
- 2016-08-25 IL IL247475A patent/IL247475B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06610A patent/ZA201606610B/en unknown
2018
- 2018-05-15 US US15/980,052 patent/US20190111058A1/en not_active Abandoned
- 2018-11-13 CY CY181101196T patent/CY1120857T1/el unknown
2020
- 2020-04-03 US US16/839,972 patent/US20210069193A1/en not_active Abandoned
2021
- 2021-12-20 US US17/556,374 patent/US20220378791A1/en active Pending

Publication	Publication Date	Title
JP2017506659A5 (2)	2018-04-12
US20220241261A1 (en)	2022-08-04	Combinations of inhibitors of irak4 with inhibitors of btk
FI3773593T3 (fi)	2024-06-18	Hidradenitis suppurativan hoito jak-estäjiä käyttäen
IL288243B1 (en)	2023-07-01	Heteroaryl-substituted pyridines and methods of use
JP2015500862A5 (2)	2016-02-18
TWI481608B (zh)	2015-04-21	作為ｊａｋ抑制劑之咪唑並吡啶衍生物
JP2018529743A5 (2)	2019-11-14
JP2009542639A5 (2)	2010-08-12
JP2020512343A5 (2)	2021-05-06
JP2017530999A5 (2)	2018-04-05
JP2011515462A5 (2)	2012-05-17
JP2014521711A5 (2)	2016-09-15
RU2012136643A (ru)	2014-06-10	[5,6]- гетероциклическое соединение
JP2019523233A5 (2)	2020-07-30
JP2009542638A5 (2)	2010-08-12
JP2022513409A5 (2)	2022-11-08
HRP20140265T1 (hr)	2014-04-25	Derivat aminopirazina i odgovarajuä†i lijek
JP2012501312A5 (2)	2012-10-11
CA2515197A1 (en)	2004-09-10	Pyrazolopyridine derivates
US11660301B2 (en)	2023-05-30	Combination of ATR kinase inhibitors with PARP inhibitors
RU2012127760A (ru)	2014-01-20	Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
RU2016129953A (ru)	2018-01-30	Фармацевтические комбинации
JP2021501145A5 (2)	2021-12-09
JP2018090566A5 (2)	2020-12-24
JP2014065716A (ja)	2014-04-17	関節炎の治療方法